Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinase (MAPK) pathway plays a sig-nificant role in the pathogenesis of these tumours, and about 2 to 20% of LGSOC harbour a BRAF mutation. Here we present a case report of two patients with a BRAF V600E mutation that achieved sustained clinical responses with combination treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).

Automated summary

Low-grade serous ovarian cancer (LGSOC) is a distinct entity from high-grade serous ovarian cancer, and its chemoresistance limits treatment options. The mitogen-activated protein kinase (MAPK) pathway plays a significant role in the pathogenesis of LGSOC, with some patients harboring BRAF mutations. Two patients with BRAF V600E mutation achieved sustained clinical responses with combination treatment of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).